Press Room
Duchesnay invests $3 million at its Blainville plant and increases its export capacity
Population Council and Duchesnay Announce New International License Agreement for ANNOVERA®
Proctofoam-HC® Back in Canadian Pharmacies
Duchesnay Inc. is seeking Health Canada's approval for ospemifene for the treatment of moderate to severe dyspareunia and vaginal dryness, symptoms of vulvar and vaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM)
Prevegyne®, the ONLY 6-day vaginal tablet treatment for non-specific vaginitis/bacterial vaginosis, now with the convenience of a vaginal applicator
Duchesnay Donates $18,500 to Moisson Laurentides Food Bank
